Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06139510 · ClinicalTrials.gov registry record · NA

Predictors of Pain in Sickle Cell Disease

A NA study of Chronic Pain and Sickle Cell Disease, sponsored by Duke University.

Recruiting
Registry status
NA
Development phase
70
Enrollment target
1
Study location

NCT06139510: Recruiting NA study of Chronic Pain and Sickle Cell Disease, sponsored by Duke University.

NCT06139510 is a NA study of Chronic Pain and Sickle Cell Disease that is actively recruiting participants, run by Duke University. The registered enrollment target is 70 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06139510, a NA study of Chronic Pain and Sickle Cell Disease, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
NA
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

Sickle cell disease is a painful inherited disorder that affects approximately 100,000 people in the United States, and more than half of these individuals develop chronic or persistent pain that is often severe and disabling. The factors that predict whether an individual with sickle cell disease will develop severe, disabling pain are unclear. The goal of this project is to identify the factors that predict severe pain outcomes in individuals living with sickle cell disease in order to improve pain management strategies and guide future studies of non-opioid therapies for treatment of their pain. Participants who agree to enroll in this study will be asked to participate in a virtual and then an in-person study visit for their full initial study assessment. They will answer survey questions during the virtual visit, and will be asked to complete several types of standard testing to understand how their body handles pain during the in-person visit. After completing the virtual and in-person sessions, participants will receive text or electronic medical record messages with brief survey (will take less than 8 minutes to complete) on their pain experiences every three months until the study is completed (or up to 48 months for people who are enrolled at the beginning of the study).

Primary Outcome

Will be determined by answering the severity subscale of the Brief Pain Inventory

Interventions

  • OTHER Quantitative sensory testing

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2024-07-12
Est. Completion 2028-06
Phase NA
Duke University

1,725 total trials

What NCT06139510 shows while recruiting

NCT06139510 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which Quantitative sensory testing is the first listed.

NCT06139510 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT06139510 about?

NCT06139510 is a clinical study titled "Predictors of Pain in Sickle Cell Disease". Sickle cell disease is a painful inherited disorder that affects approximately 100,000 people in the United States, and more than half of these individuals develop chronic or persistent pain that is often severe and disabling. The factors that predict whether an individual with sickle cell disease w...

What is the current status of trial NCT06139510?

This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2024-07-12. Estimated completion is 2028-06.

What conditions does trial NCT06139510 study?

This clinical trial studies the following conditions: Chronic Pain, Sickle Cell Disease.

What interventions are being tested in trial NCT06139510?

The interventions under investigation include: Quantitative sensory testing (OTHER).

Who is sponsoring clinical trial NCT06139510?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06139510 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06139510's enrollment target sits among peer trials

70 167th of 301 higher than 134 of 301 other Chronic Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06139510, the US trial registry maintained by the National Library of Medicine. NCT06139510 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.